{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Defined as the dose level at which =\\< 1 of 6 subjects experience dose limiting toxicity.","groups":[{"description":"Patients receive doxorubicin hydrochloride IV, vinblastine sulfate IV, and dacarbazine IV on days 1 and 15. Patients also receive brentuximab vedotin IV over 30 minutes on days 1 and 15. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity.\n\nBrentuximab Vedotin: Given IV\n\nDacarbazine: Given IV\n\nDoxorubicin Hydrochloride: Given IV\n\nPharmacological Study: Correlative studies\n\nVinblastine: Given IV","id":"OG000","title":"Treatment (Brentuximab and Combination Chemotherapy)"}],"paramType":"NUMBER","populationDescription":"Participants entered into the phase I portion of the study","reportingStatus":"POSTED","timeFrame":"28 days","title":"Maximal Tolerated Dose of Brentuximab Vedotin (Phase I)","type":"PRIMARY","unitOfMeasure":"mg/kg"}